ImmunityBio Reports Long-Term ANKTIVA Data in Bladder Cancer Study
ImmunityBio said long-term data from its Phase 2/3 QUILT-3.032 study (N=100) were published in the Journal of Urology. The study reported 84% cystectomy avoidance at three years and complete responses beyond 53 months among patients receiving ANKTIVA plus BCG for BCG-unresponsive NMIBC with CIS, with or without papillary tumors.
ImmunityBio, Inc. (NASDAQ:IBRX), a commercial-stage immunotherapy company, announced that long-term findings from the Phase 2/3 QUILT-3.032 study (N=100) have been published in the Journal of Urology. The study assessed ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette…